RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 AXIS 2 Clinical Outcomes No Different than Placebo
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 1
SP 12
OP 13
DO 10.1177/155989771201004
UL http://mdc.sagepub.com/content/12/1/12.abstract
AB AX200 was a novel and promising drug candidate with a comprehensive preclinical and clinical package that fulfilled Stroke Therapy Academic Industry Roundtable (STAIR) and European Stroke Organization recommendations; yet, no difference was observed in clinical outcome or imaging compared with placebo in acute ischemic stroke patients, according to results from the AX200 for the Treatment of Ischemic Stroke Phase 3 trial [AXIS-2; NCT00927836].